Payment overview · 2025
General Payments
$3,020.28
122 reported records · 36 companies
Healthcare provider profile · identity verified
Brian Escala Chavez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LAKE FOREST, CA · NPI 1215974969
Verified facts
What the public records show
CMS Open Payments records show Brian Escala Chavez, M.D. received $3,020.28 in general payments during 2025 across 122 reported records.
Amgen Inc. accounted for 12.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 46 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Afrezza, Jardiance, Kerendia, Mounjaro, Ozempic, Prolia, Rybelsus, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 276 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Trulicity by this doctor in 2024.
Mannkind Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AFREZZA as an associated drug or biological on 10645 records involving 3625 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Afrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 262 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tresiba by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $373.18 | 12.4% | 16 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $238.14 | 7.9% | 7 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $214.79 | 7.1% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $213.25 | 7.1% | 9 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $200.50 | 6.6% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $191.37 | 6.3% | 13 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $189.08 | 6.3% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $177.69 | 5.9% | 7 | 2025 |
| NEW WORLD MEDICAL,INC. | Unresolved — no canonical attribution shown | $147.43 | 4.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $145.26 | 4.8% | 6 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $114.84 | 3.8% | 4 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $99.87 | 3.3% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $72.76 | 2.4% | 3 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $54.44 | 1.8% | 2 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $50.66 | 1.7% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.55 | 1.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.51 | 1.4% | 2 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.04 | 1.4% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $34.53 | 1.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $34.41 | 1.1% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $28.06 | 0.9% | 1 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.15 | 0.9% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.74 | 0.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.89 | 0.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.28 | 0.7% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $21.29 | 0.7% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $21.10 | 0.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.89 | 0.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.71 | 0.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.71 | 0.7% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $19.93 | 0.7% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $18.51 | 0.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.41 | 0.6% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $17.32 | 0.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.01 | 0.5% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $13.98 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,020.28 | 122 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $238.14 | 7 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $213.25 | 9 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $200.50 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $189.35 | 8 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $189.08 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $177.69 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $163.71 | 3 | 2025 |
Source payment records
|
|||||
| Ahmed Glaucoma Valve Normalized: ahmed glaucoma valve |
Device | NEW WORLD MEDICAL,INC. | $147.43 | 1 | 2025 |
Source payment records
|
|||||
| Clearpath Normalized: clearpath |
Device | NEW WORLD MEDICAL,INC. | $147.43 | 1 | 2025 |
Source payment records
|
|||||
| Kahook Dual Blade Normalized: kahook dual blade |
Device | NEW WORLD MEDICAL,INC. | $147.43 | 1 | 2025 |
Source payment records
|
|||||
| Streamline Normalized: streamline |
Device | NEW WORLD MEDICAL,INC. | $147.43 | 1 | 2025 |
Source payment records
|
|||||
| Via360 Normalized: via360 |
Device | NEW WORLD MEDICAL,INC. | $147.43 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $144.80 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $123.02 | 9 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $114.84 | 4 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $99.87 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $93.24 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $79.72 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $72.76 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $65.54 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $64.67 | 4 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $57.38 | 2 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $54.44 | 2 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $50.66 | 2 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $47.55 | 2 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $42.04 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $34.53 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $34.41 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $30.83 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $28.06 | 1 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $26.74 | 1 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AFREZZA afrezza |
2025 | Afrezza | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 214 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 85 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 262 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 18 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 54 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 276 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
276 | 65 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
18 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
73 | 17 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
214 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
214 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
85 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
103 | 23 |
| Mannkind Corporation Exact reporting entity; no affiliate inference |
2025 | AFREZZA open payments reported associated product |
CMS Open Payments — General Payments 10645 supporting records · 3625 recipient NPIs · example record 1250869202 |
Afrezza · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
262 | 57 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 475 | 124 |
| Metformin Hcl Er | Metformin Hcl | 288 | 84 |
| Synthroid | Levothyroxine Sodium | 276 | 65 |
| Atorvastatin Calcium | Atorvastatin Calcium | 272 | 77 |
| Ozempic | Semaglutide | 262 | 57 |
| Jardiance | Empagliflozin | 214 | 49 |
| Ezetimibe | Ezetimibe | 206 | 57 |
| Metformin Hcl | Metformin Hcl | 203 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 184 | 58 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 126 | 41 |
| Losartan Potassium | Losartan Potassium | 105 | 30 |
| Trulicity | Dulaglutide | 103 | 23 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 99 | 37 |
| Mounjaro | Tirzepatide | 85 | 18 |
| Acarbose | Acarbose | 74 | 26 |
| Farxiga | Dapagliflozin Propanediol | 73 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 73 | 29 |
| Liothyronine Sodium | Liothyronine Sodium | 71 | 19 |
| Lisinopril | Lisinopril | 67 | 18 |
| Amlodipine Besylate | Amlodipine Besylate | 66 | 19 |
| Allopurinol | Allopurinol | 65 | 16 |
| Simvastatin | Simvastatin | 60 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 11 |
| Rybelsus | Semaglutide | 54 | 14 |
| Methimazole | Methimazole | 51 | 14 |
| Januvia | Sitagliptin Phosphate | 48 | 11 |
| Kerendia | Finerenone | 46 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 45 | suppressed |
| Calcitriol | Calcitriol | 36 | suppressed |
| Repatha Sureclick | Evolocumab | 36 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 35 | suppressed |
| Armour Thyroid | Thyroid,pork | 34 | suppressed |
| Glimepiride | Glimepiride | 34 | 12 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 34 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | 11 |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Nateglinide | Nateglinide | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Testosterone | Testosterone | 25 | suppressed |
| Gabapentin | Gabapentin | 24 | suppressed |
| Humalog | Insulin Lispro | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Levoxyl | Levothyroxine Sodium | 23 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Omeprazole | Omeprazole | 22 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 21 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 20 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 19 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 18 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 18 | suppressed |
| Prolia | Denosumab | 18 | 11 |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Carvedilol | Carvedilol | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Tresiba | Insulin Degludec | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Afrezza | Insulin Regular, Human | 11 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Humatrope | Somatropin | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,020.28 · 122 records | Amgen Inc. | ACTHAR, AFREZZA, AIRSUPRA, AZMIRO, Ahmed Glaucoma Valve, CRENESSITY, CRYSVITA, Clearpath, EVENITY, FREESTYLE LIBRE 3, FUROSCIX, JARDIANCE, JATENZO, JYNARQUE, Kahook Dual Blade, Kerendia, Korlym, LEQVIO, MOUNJARO, NP Thyroid 60, Omnipod, Ozempic, PROLIA, QUTENZA, RECORLEV, REPATHA, REZDIFFRA, Rybelsus, SAPHNELO, SYNTHROID, Streamline, TEPEZZA, TZIELD, The Cologuard Plus Collection Kit, Tlando, Tymlos, UBRELVY, VOQUEZNA, Veozah, Via360, Wegovy, XYOSTED, Yorvipath, ZAVZPRET, ZORYVE, t:slim X2 Insulin Pump with Control-IQ | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Afrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error